Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 6/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.40 |
| ▸ | CA5A | P35218 | 1/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.40 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.38 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.38 |
| ▸ | HINT1 | P49773 | 1/20 | 0.37 |
| ▸ | AHCY | P23526 | 3/20 | 0.36 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4394104 | 0.89 | AHCY (0.43) | NT5EHIF1AADORA3ADORA1AHCY | |
| SCHEMBL3661441 | 0.88 | ADORA3 (0.44) | NT5EADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL28657282 | 0.73 | NT5E (0.57) | NT5ELMNAHIF1AADORA3ADORA2A | |
| SCHEMBL3365589 | 0.72 | PRMT5 (0.46) | NT5EHIF1AADORA3ADORA2AADORA1 | |
| SCHEMBL5038453 | 0.72 | AHCY (0.44) | NT5EHIF1AADORA1AHCY | |
| SCHEMBL5040710 | 0.71 | ADORA3 (0.45) | NT5EADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL24980458 | 0.70 | CA5A (0.67) | NT5ELMNAHIF1AADORA3ADORA2A | |
| SCHEMBL13769822 | 0.69 | P2RY11 (0.50) | NT5ELMNAHIF1AADORA3ADORA2A | |
| SCHEMBL8925141 | 0.68 | PDE2A (0.59) | NT5ELMNAHIF1ACA5AHINT1 | |
| SCHEMBL8925127 | 0.68 | PDE2A (0.59) | NT5ELMNAHIF1ACA5AHINT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11298432-B2 | Method for preparing a marked purine derivative, said derivative and uses thereof | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2022-04-12 | — | — | US | disclosed |
| EP-2238139-B1 | METHOD FOR PREPARING A MARKED PURINE DERIVATIVE, SAID DERIVATIVE AND USES THEREOF | COMMISSARIAT L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2017-09-27 | — | — | EP | disclosed |
| US-20150238640-A1 | METHOD FOR PREPARING A MARKED PURINE DERIVATIVE, SAID DERIVATIVE AND USES THEREOF | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2015-08-27 | — | — | US | disclosed |
| US-20100290990-A1 | METHOD FOR PREPARING A MARKED PURINE DERIVATIVE, SAID DERIVATIVE AND USES THEREOF | BARRE LOUISA | 2010-11-18 | — | — | US | disclosed |
| EP-2238139-A2 | METHOD FOR PREPARING A MARKED PURINE DERIVATIVE, SAID DERIVATIVE AND USES THEREOF | Commissariat à l'Énergie Atomique et aux Énergies Alternatives (FR) | 2010-10-13 | — | — | EP | disclosed |
| WO-2009087066-A2 | METHOD FOR PREPARING A MARKED PURINE DERIVATIVE, SAID DERIVATIVE AND USES THEREOF | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2009-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11298432-B2 | Method for preparing a marked purine derivative, said derivative and uses thereof | TPMT, NUDT1, DUT | NT5E 19/4885LMNA 3403/4885HIF1A 2007/4885 |
| US-20150238640-A1 | METHOD FOR PREPARING A MARKED PURINE DERIVATIVE, SAID DERIVATIVE AND USES THEREOF | TPMT, NUDT1, DUT | NT5E 19/4885LMNA 3403/4885HIF1A 2007/4885 |
| US-20100290990-A1 | METHOD FOR PREPARING A MARKED PURINE DERIVATIVE, SAID DERIVATIVE AND USES THEREOF | TPMT, NUDT1, DUT | NT5E 19/4885LMNA 3403/4885HIF1A 2007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.